Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

• Drug: Erlotinib
  
  Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
• Drug: Erlotinib
  
  For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
• Drug: PF-02341066
  
  For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2

• Active Comparator: Erlotinib
  
  Intervention: Drug: Erlotinib
• Experimental: Erlotinib + PF-02341066
  
  Interventions:
  

  • Drug: Erlotinib
  • Drug: PF-02341066

Inclusion Criteria:

• histologically proven diagnosis of Non-Small Cell Lung Cancer (NSCLC) that is locally advanced or metastatic and of the adenocarcinoma subtype (including mixed adenosquamous histology)
• evident disease progression by Response Evaluation Criterion in Solid Tumors (RECIST) after at least one but no more than 2 chemotherapy regimens for advanced disease
• tumors must have measurable disease as per RECIST

Exclusion Criteria:

• known interstitial lung disease
• prior treatment with an agent that is known or proposed to be active by action on EGFR tyrosine kinase or c-Met/HGF (Phase 2 Portion)